CairnSurgical, Inc. is focused on revolutionizing breast-conserving surgery through its innovative Breast Cancer Locator™ System (BCL™). This proprietary technology addresses the significant challenge of achieving clear surgical margins, which is crucial for successful tumor removal. The BCL™ System utilizes a patient-specific, 3D-printed surgical guidance approach that provides surgeons with a detailed blueprint of the tumor's location, size, shape, and depth. This advanced visualization capability is designed to enhance precision during surgery, thereby reducing the likelihood of re-excision, which currently affects over 20% of breast-conserving surgeries.

The BCL™ System is complemented by the Visualizer™, an interactive tool that offers a 3D view of the tumor area while the patient is in the supine position, aligning with the surgical setup. This innovative approach contrasts with traditional methods, such as wire or seed localization, which can be invasive and uncomfortable for patients. By providing real-time, accurate guidance, the BCL™ System aims to improve surgical outcomes and patient confidence, ultimately striving to eliminate the need for additional surgeries due to incomplete tumor removal.

United States

CairnSurgical, Inc. is a clinical stage medical device company developing patient-specific surgical guides using patient imaging data and state-of-the-art 3D printing technologies. CairnSurgical's Breast Cancer Locator System enables precise tumor localization and excision, and has been tested in both single-arm and randomized clinical trials.

The Breast Cancer Locator is considered an investigational device in the U.S. and is limited by U.S. law to investigational use only. It is not approved for sale in any region.

CairnSurgical, Inc.

Company Details